CTCBIO Inc. (060590.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩2,690 (-1.10%) as of
Key statistics
- Market cap
- 64.31B
- Dividend yield
- 0.00%
- 52-week range
- 2,570.00 – 5,610.00
- Beta
- -0.03
- Revenue (TTM)
- 131.54B
- Profit margin
- 5.71%
- Volume
- 8.36k
About CTCBIO Inc.
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19. In addition, the company offers coating base/plasticizer/pore former, diluting agents, bonding agents, disintegrating agents, lubricants, solubilizer/biopharma, topicals, APIs, and food/health functional foods, as well as animal drugs, physiological activators, functional enhancers, and disinfectants. CTCBIO Inc. was founded in 1993 and is headquartered in Hwaseong-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hwaseong-si, South Korea
- Employees
- 226
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.